• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Mechanisms of topoisomerase I inhibition by anticancer drugs.

作者信息

Pommier Y, Tanizawa A, Kohn K W

机构信息

National Institutes of Health, Bethesda, Maryland 20892, USA.

出版信息

Adv Pharmacol. 1994;29B:73-92. doi: 10.1016/s1054-3589(08)61132-1.

DOI:10.1016/s1054-3589(08)61132-1
PMID:8996602
Abstract
摘要

相似文献

1
Mechanisms of topoisomerase I inhibition by anticancer drugs.抗癌药物抑制拓扑异构酶I的机制。
Adv Pharmacol. 1994;29B:73-92. doi: 10.1016/s1054-3589(08)61132-1.
2
Clinical trials using irinotecan.使用伊立替康的临床试验。
J Pediatr Hematol Oncol. 2002 Feb;24(2):84-5. doi: 10.1097/00043426-200202000-00002.
3
[Homocamptothecins--novel promising anticancer drugs as inhibitors of topoisomerase I].[喜树同系物——作为拓扑异构酶I抑制剂的新型有前景的抗癌药物]
Yao Xue Xue Bao. 2004 May;39(5):396-400.
4
Eukaryotic DNA topoisomerase I: genome gatekeeper and its intruders, camptothecins.真核生物DNA拓扑异构酶I：基因组守护者及其入侵者——喜树碱
Semin Oncol. 1996 Feb;23(1 Suppl 3):3-10.
5
Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro.聚（ADP-核糖）聚合酶（PARP）抑制剂NU1025对体外培养的L1210细胞中拓扑异构酶I和II抑制剂细胞毒性的差异影响。
Br J Cancer. 2001 Jan 5;84(1):106-12. doi: 10.1054/bjoc.2000.1555.
6
Combined effects of hyperthermia and CPT-11 on DNA strand breaks in mouse mammary carcinoma FM3A cells.热疗与伊立替康联合作用对小鼠乳腺癌FM3A细胞DNA链断裂的影响
Anticancer Res. 1995 Jan-Feb;15(1):83-6.
7
Camptothecin resistance related to drug-induced down-regulation of topoisomerase I and to steps occurring after the formation of protein-linked DNA breaks.
Ann N Y Acad Sci. 1996 Dec 13;803:74-92. doi: 10.1111/j.1749-6632.1996.tb26378.x.
8
Drug resistance mechanisms of topoisomerase I drugs.拓扑异构酶I类药物的耐药机制。
Adv Pharmacol. 1994;29B:93-103. doi: 10.1016/s1054-3589(08)61133-3.
9
Differential GADD45, p21CIP1/WAF1, MCL-1 and topoisomerase II gene induction and secondary DNA fragmentation after camptothecin-induced DNA damage in two mutant p53 human colon cancer cell lines.喜树碱诱导的DNA损伤后，两种p53突变型人结肠癌细胞系中GADD45、p21CIP1/WAF1、MCL-1和拓扑异构酶II基因的差异诱导及继发性DNA片段化
Oncol Res. 1996;8(7-8):317-23.
10
Camptothecin and minor-groove binder hybrid molecules: synthesis, inhibition of topoisomerase I, and anticancer cytotoxicity in vitro.喜树碱与小沟结合剂杂合分子：合成、拓扑异构酶I抑制及体外抗癌细胞毒性
J Med Chem. 1997 Jan 17;40(2):216-25. doi: 10.1021/jm9605804.

引用本文的文献

1
Molecular Mechanisms of Cytotoxicity of NCX4040, the Non-Steroidal Anti-Inflammatory NO-Donor, in Human Ovarian Cancer Cells.NCX4040，一种非甾体类抗炎药一氧化氮供体，在人卵巢癌细胞中的细胞毒性的分子机制。
Int J Mol Sci. 2022 Aug 3;23(15):8611. doi: 10.3390/ijms23158611.
2
Co-Delivery of CPT-11 and Panobinostat with Anti-GD2 Antibody Conjugated Immunoliposomes for Targeted Combination Chemotherapy.CPT-11和帕比司他与抗GD2抗体偶联免疫脂质体联合递送用于靶向联合化疗。
Cancers (Basel). 2020 Oct 31;12(11):3211. doi: 10.3390/cancers12113211.
3
Elucidation of Mechanisms of Topotecan-Induced Cell Death in Human Breast MCF-7 Cancer Cells by Gene Expression Analysis.
通过基因表达分析阐明拓扑替康诱导人乳腺癌MCF-7细胞死亡的机制
Front Genet. 2020 Jul 17;11:775. doi: 10.3389/fgene.2020.00775. eCollection 2020.
4
Structural Recognition and Binding Pattern Analysis of Human Topoisomerase II Alpha with Steroidal Drugs: In Silico Study to Switchover the Cancer Treatment.人拓扑异构酶 IIα与甾体药物的结构识别和结合模式分析：切换癌症治疗的计算机研究。
Asian Pac J Cancer Prev. 2020 May 1;21(5):1349-1355. doi: 10.31557/APJCP.2020.21.5.1349.
5
Topoisomerase I inhibitor, irinotecan, depletes regulatory T cells and up-regulates MHC class I and PD-L1 expression, resulting in a supra-additive antitumor effect when combined with anti-PD-L1 antibodies.拓扑异构酶I抑制剂伊立替康可消耗调节性T细胞并上调MHC I类分子和PD-L1的表达，与抗PD-L1抗体联合使用时会产生超相加抗肿瘤作用。
Oncotarget. 2018 Jul 31;9(59):31411-31421. doi: 10.18632/oncotarget.25830.
6
Synergistic enhancement of topotecan-induced cell death by ascorbic acid in human breast MCF-7 tumor cells.抗坏血酸增强拓扑替康诱导人乳腺癌 MCF-7 肿瘤细胞死亡的协同作用。
Free Radic Biol Med. 2017 Dec;113:406-412. doi: 10.1016/j.freeradbiomed.2017.10.377. Epub 2017 Oct 24.
7
Nitric oxide inhibits ATPase activity and induces resistance to topoisomerase II-poisons in human MCF-7 breast tumor cells.一氧化氮抑制人MCF-7乳腺癌细胞中的ATP酶活性并诱导对拓扑异构酶II抑制剂的抗性。
Biochem Biophys Rep. 2017 Apr 20;10:252-259. doi: 10.1016/j.bbrep.2017.04.011. eCollection 2017 Jul.
8
Discovery of DNA Topoisomerase I Inhibitors with Low-Cytotoxicity Based on Virtual Screening from Natural Products.基于天然产物虚拟筛选的低细胞毒性DNA拓扑异构酶I抑制剂的发现
Mar Drugs. 2017 Jul 9;15(7):217. doi: 10.3390/md15070217.
9
Nitric oxide inhibits topoisomerase II activity and induces resistance to topoisomerase II-poisons in human tumor cells.一氧化氮抑制拓扑异构酶II的活性，并诱导人类肿瘤细胞对拓扑异构酶II抑制剂产生抗性。
Biochim Biophys Acta. 2016 Jul;1860(7):1519-27. doi: 10.1016/j.bbagen.2016.04.009. Epub 2016 Apr 17.
10
Review of systemic therapies for locally advanced and metastatic rectal cancer.局部晚期和转移性直肠癌全身治疗的综述
J Gastrointest Oncol. 2015 Apr;6(2):185-200. doi: 10.3978/j.issn.2078-6891.2014.112.